CORT - Major Decision: Gary Charles Robb Exercises Options Realizing $356K At Corcept Therapeutics | Benzinga
A substantial insider activity was disclosed on December 7, as Robb, Chief Business Officer at Corcept Therapeutics (NASDAQ:CORT), reported the exercise of a large sell of company stock options.
What Happened: Robb, Chief Business Officer at Corcept Therapeutics, exercised stock options for 15,000 shares of CORT stock. This information was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday. The exercise price of the options was $3.29 per share.
During Thursday's morning session, Corcept Therapeutics shares down by 0.0%, currently priced at $27.04. Considering the current price, Robb's 15,000 shares have a total value of $356,250.
All You Need to Know About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Financial Insights: Corcept Therapeutics
Revenue Growth: Corcept Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 21.5%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the ...